This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (49)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

A Trial of Ganciclovir vs Immunoglobulin

David J. Conti, MD; Brian M. Freed, PhD; Scott A. Gruber, MD, PhD; Neil Lempert, MD

Arch Surg. 1994;129(4):443-447.

Abstract
Objective
To compare the efficacy, safety, and cost of prophylactic low-dose ganciclovir with that of immunoglobulin in renal transplant recipients at risk for primary cytomegalovirus (CMV) disease.

Design and Setting
A prospective, randomized trial at a 650-bed tertiary medical center hospital.

Patients
Fifty-one consecutive CMV-seronegative patients who received renal allografts from seropositive donors between March 1990 and April 1992.

Main Outcome Measures
Patient and allograft survival, and the incidence and severity of CMV disease.

Intervention
Cytomegalovirus prophylaxis with seven doses of intravenous immunoglobulin for 6-week periods (group 1, n=27) or low-dose intravenous ganciclovir for 3 weeks (group 2, n=24). Results were compared with those obtained in 23 CMV-seronegative historical positive donors between 1987 and 1989, and who did n-positive donors between 1987 and 1989, and who did not receive prophylaxis for CMV (group 3).

Results
Both prophylactic regimens significantly reduced the incidence of invasive CMV infection (P<.05) and were well tolerated. However, the cost of ganciclovir ($350 per patient) was substantially less than that of immunoglobulin ($4000 per patient).

Conclusions
These data suggest that prophylactic ganciclovir therapy provides a cost-effective approach toward significantly improving the outcome of renal transplantation in recipients at risk for primary CMV disease.

(Arch Surg. 1994;129:443-447)

Author Affiliations
From the Department of Surgery, Section of Transplantation, Albany (NY) Medical College.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Longitudinal Analysis of Levels of Immunoglobulins against BK Virus Capsid Proteins in Kidney Transplant Recipients
Randhawa et al.
CVI 2008;15:1564-1571.
ABSTRACT | FULL TEXT  

Management of herpes virus infections following transplantation
J Antimicrob Chemother 2000;45:729-748.
FULL TEXT  

New Strategies for Prevention and Therapy of Cytomegalovirus Infection and Disease in Solid-Organ Transplant Recipients
Sia and Patel
Clin. Microbiol. Rev. 2000;13:83-121.
ABSTRACT | FULL TEXT  

Preemptive Ganciclovir Therapy in Cytomegalovirus-Seropositive Renal Transplants Recipients
Conti et al.
Arch Surg 1995;130:1217-1222.
ABSTRACT